Tomaszewski, William H. http://orcid.org/0000-0001-7870-3935
Waibl-Polania, Jessica
Chakraborty, Molly http://orcid.org/0000-0002-1372-8012
Perera, Jonathan http://orcid.org/0000-0003-3224-6075
Ratiu, Jeremy http://orcid.org/0000-0001-9234-7674
Miggelbrink, Alexandra http://orcid.org/0000-0003-1499-2269
McDonnell, Donald P. http://orcid.org/0000-0002-7331-4700
Khasraw, Mustafa http://orcid.org/0000-0003-3249-9849
Ashley, David M.
Fecci, Peter E. http://orcid.org/0000-0002-2912-8695
Racioppi, Luigi http://orcid.org/0000-0002-9207-6752
Sanchez-Perez, Luis
Gunn, Michael D. http://orcid.org/0000-0003-4602-0667
Sampson, John H. http://orcid.org/0000-0002-0104-7658
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (5R01-NS099463-04, 5P01-CA225622-03, 1R01-CA235612-02, 5P50-CA190991-07, 3P50-CA190991-07S1, 1R01-NS116888-0A1)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 24 February 2022
Accepted: 14 October 2022
First Online: 29 October 2022
Competing interests
: P.E.F. reports consulting for Monteris Medical. J.H.S. has an equity interest in Istari Oncology, which has licensed intellectual property from Duke related to the use of poliovirus and D2C7 in the treatment of glioblastoma. J.H.S. is an inventor on patents related to the PEP-CMV DC vaccine with tetanus (US 9974848), as well as poliovirus vaccine (US 11406677) in the treatment of glioblastoma. J.H.S. has an equity interest in Annias Immunotherapeutics, which has licensed intellectual property from Duke University Medical Center related to the use of the pepCMV vaccine in the treatment of glioblastoma. M.K. reports receiving institutional research funding from AbbVie, Bristol Myers Squibb, Celldex and Specialized Therapeutics. M.K. additionally reports consulting/advisory roles with Voyager Therapeutics, AbbVie, Bristol Myers Squibb, Janssen and Janssen, Eli Lilly, Ipsen, Pfizer, and Roche. L.R. and D.P.M. have applied for a patent covering the use of CaMKK2. The remaining authors declare no other competing interests.